The Recombinant Human VEGF-A/VEGF165 Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating VEGF-A/VEGF165 function and its implications in health and disease.
This product (SKU: RPCB0870) is produced using HEK293 cells and features a N-His tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 20.01 kDa with an observed molecular weight of 24-26 kDa under denaturing conditions, achieving ≥ 95 % as determined by SDS-PAGE;≥ 95 % as determined by HPLC.. Functional bioactivity has been validated through rigorous quality control assays, confirming its suitability for demanding research applications.
Key Features
High Purity by Affinity Chromatography
Mammalian & Bacterial Expression Systems
High lot-to-lot consistency via strict QC
Product Name:
Recombinant Human VEGF-A/VEGF165 Protein
SKU:
RPCB0870
Size:
10 μg , 20 μg , 50 μg , 100 μg
Reactivity:
Human
Synonyms:
VEGFA, MVCD1, VEGF, VPF, vascular endothelial growth factor A, MVCD1, VEGF, VPF, L VEGFA, VEGF A
High quality, high purity and low endotoxin recombinant Recombinant Human VEGF-A/VEGF165 Protein (RPCB0870), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 0.1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by SDS-PAGE;≥ 95 % as determined by HPLC.
Formulation:
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.
Bio-Activity:
Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human VEGF165 at 1 μg/mL (100 μL/well) can bind Recombinant Human VEGFR2 with a linear range of 8-20 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165 at 2 μg/mL (100 μL/well) can bind Human KDR with a linear range of 0.2-11.6 ng/mL.
Recombinant Human VEGF165 stimulates cell proliferation of the human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 0.19-0.78 ng/mL, corresponding to a specific activity of 1.28 × 106~5.26× 106 units/mg.
Reconstitution:
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.
Storage:
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.
Recombinant Human VEGF-A/VEGF165 Protein was determined by SDS-PAGE under reducing (R) and non-reducing (NR) conditions.
The purity of human VEGF165 Protein (RPCB0870) was greater than 95% as determined by SEC-HPLC.
Immobilized Recombinant Human VEGF165 at 2 μg/mL (100 μL/well) can bind Human KDR with a linear range of 0.2-11.6 ng/mL.
Recombinant Human VEGF165 stimulates cell proliferation of the human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 0.19-0.78 ng/mL, corresponding to a specific activity of 1.28 × 106~5.26× 106 units/mg.
